Tuesday, May 27, 2008 5:31:00 AM PDT | VentureDeal Staff
HyperMed is applying hyperspectral technology to medical
applications via its flagship diagnostic device, the OxyVu-1, which has
received FDA clearance for use in assessing patients for poor tissue
GBP Capital made the investment. The company said the proceeds would be used
to support its ongoing marketing and sales initiatives of its lead product.
Email Page | Print Page
Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?
Start your Free 14 Day Trial now – no obligation or credit card required.
Founded in 2006, VentureDeal is a database that provides the latest information about venture capital firms, venture-backed technology companies and transactions throughout North America.
Learn More »
Email Sign Up
© 2014 VentureDeal, Inc., Menlo Park, CA. All Rights Reserved.